Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.
OBJECTIVE. To evaluate the effects of short term use of dutasteride and Serenoarepens before transurethral resection of the prostate (TURP) on the amount of intraoperative blood loss and microvessel density (MVD) of prostatic stromal and suburethral tissues in the patients with benign prostatic hyperplasia.


METHODS
The study involved 75 male patients who planned to have a TURP. The patients were randomly divided into three groups. The control group comprised 21 patients. Group 2 comprised 27 patients who used dutasteride 5 mg/day, and group 3 comprised 27 patients who used S. repens 160 mg/day for 5 weeks before the operation. The amount of intraoperative haemorrhage was calculated. Total blood loss, total blood loss/time, total blood loss/weight of resected tissue and total blood loss/weight/time were calculated for each patient and all were recorded. Sections from the prostatic stromal and suburethral tissues were examined for suburethral and prostatic MVD.


RESULTS
The total amount of intraoperative blood loss, total blood loss/time, total blood loss/weight of resected tissue, total blood loss/weight/time, serum haemoglobin level change, prostatic MVD and suburethral MVD of the groups were compared. No significant statistical differences were found between the groups for any of these variables (p > 0.05).


CONCLUSIONS
Dutasteride and S. repens therapies were not superior to control in terms of the decrease in total blood loss during TURP. Moreover, MVD showed no statistical differences in the treatment groups compared with the control group.
Tuncel
Altug
A
Ministry of Health, Ankara Numune Research and Training Hospital, Third Department of Urology, Ankara, Turkey. tuncelaltug@yahoo.com
Ener
Kemal
K
Han
Ozge
O
Nalcacioglu
Varol
V
Aydin
Omur
O
Seckin
Selda
S
Atan
Ali
A
D000368:Aged; D000369:Aged, 80 and over; D001378:Azasteroids / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D055806:Microvessels / Q000473:pathology*; D008875:Middle Aged; D008517:Phytotherapy / Q000379:methods*; D028321:Plant Preparations / Q000627:therapeutic use*; D011300:Preoperative Care / Q000379:methods; D011467:Prostate / Q000098:blood supply; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000601:surgery; D028024:Serenoa; D013997:Time Factors; D020728:Transurethral Resection of Prostate / Q000379:methods*; D016896:Treatment Outcome
D001378:Azasteroids; D004791:Enzyme Inhibitors; D028321:Plant Preparations; D000068538:Dutasteride